2022年演示材料

A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinom

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter,single-arm, open-label, phase Ib trial

Safety and efficacy of Pucotenlimab (HX008) - a Humanized Immunoglobulin G4 Monoclonal Antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

HX009, a clinical stage first-in-class PD-1xCD47 BsAb, shows strong antitumor activity in preclinical lymphoma models

ASCO 2021:First in Human Phase I Dose Escalation Study of HX009, a Novel Recombinant Humanized Anti CD47/PD 1 Bispecific Antibody, in Patients with Advanced Malignancies